In one effort, antibody-based blocking of Galectin-9, a putative TIM-3 ligand, reduced exhaustion of CAR T cells and significantly increased their cytotoxicity against previously resistant tumor cells [37]. The gene discussed is HAVCR2; the disease is neoplasm.